Navigation Links
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Date:6/14/2013

for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to its clients or for providing advice in relation to the Further Increased Offer or any other matters referred to in this announcement.

Investec Corporate Finance Ireland Limited trading as Investec is regulated by the Central Bank of Ireland and is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to clients of Investec Corporate Finance Ireland Limited or for providing advice in relation to the Further Increased Offer or any other matters referred to in this announcement.

Forward-looking Statements

This announcement may include certain "forward looking statements" with respect to the business, strategy and plans of Royalty Pharma and its expectations relating to the Further Increased Offer and Elan's future financial condition and performance. Statements that are not historical facts, including statements about Elan or Royalty Pharma or Royalty Pharma's belief and expectation, are forward looking statements. Words such as "believes", "anticipates", "estimates", "expects", "intends", "aims", "potential", "will", "would", "could", "considered", "likely", and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.

Examples of such forward looking state
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
2. Royalty Pharma Statement Regarding Elan Law Suits
3. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
4. Royalty Pharma Statement Regarding Elan Proposal
5. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
6. Cowen Healthcare Royalty Partners Raises $1 Billion
7. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
8. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
9. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
10. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
11. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across the ... for Clinical Data Management (SCDM) to provide the ... certification programs —providing access to the more than ... extends SCDM members with 10% off when registering for ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Stockholders Meeting to Approve Merger With Integra on October 11, ... ... IRVINE, California, September 5 IsoTis, Inc.,(NASDAQ: ISOT ) ... statement with the U.S. Securities and,Exchange Commission ("SEC") in connection with ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today ... the Barocycler NEP2320, a patent-pending, lightweight,compressed air driven ... that it has been issued a CB Scheme ... has been found in,compliance with the IEC 61010-1 ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
Cached Biology Technology:IsoTis Files Definitive Proxy Statement 2IsoTis Files Definitive Proxy Statement 3IsoTis Files Definitive Proxy Statement 4Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers could ... second chancejust not as they originally thought. LateTIME ... from bone marrow that were believed to have the ... injected into the heart within two weeks of the ...
... suffering from heart failure due to a previous myocardial ... year following an investigative treatment that involved infusing them ... 4 percent improvement average the researchers projected for the ... published today (Nov. 14) in The Lancet ...
... to understanding what drives tumor metastasis, as laboratory models ... their own growth. In a recent issue of ... Association for Cancer Research, Ral A. Ruggiero, Ph.D., a ... the National Academy of Medicine in Buenos Aires, Argentina, ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2Results triple researchers' projections with use of adult stem cells for heart failure 2
Permeabilization Solution, 5X...
Perm/Wash Buffer 250 Tests...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Biology Products: